Kubis Nathalie, Besnard Sandrine, Silvestre Jean-Sébastien, Feletou Michel, Huang Paul L, Lévy Bernard I, Tedgui Alain
INSERM Unit 541, Hôpital Lariboisière, Paris, France.
J Hypertens. 2002 Feb;20(2):273-80. doi: 10.1097/00004872-200202000-00017.
Hypertension in endothelial nitric oxide synthase knockout (eNOS-/-) mice is believed to be partly due to altered vasodilatation. However, nitric oxide (NO) is also known to play an important part in angiogenesis.
To investigate whether capillary and arteriolar density were impaired in eNOS-/- mice, as this could account for increased vascular resistance and hypertension.
Using immunohistochemistry with mouse monoclonal smooth muscle alpha-actin antibody to detect arterioles and rabbit polyclonal fibronectin antibody to detect capillaries, we quantified arteriolar and capillary density in the left ventricle and in the gracilis muscle from eNOS-/- mice compared with those in C57BL6J littermates (n = 6-8) in 8- and in 12-week-old mice. In a second set of experiments, we treated 8-week-old normotensive eNOS-/- mice with the antihypertensive vasodilator, hydralazine, for 1 month.
Eight-week-old eNOS-/- mice were normotensive and presented similar arteriolar and capillary densities in cardiac and skeletal muscles compared with those in eNOS+/+ mice. Twelve-week-old eNOS/- mice were hypertensive (mean arterial pressure 118 +/- 21 mmHg compared with 64 +/- 2 mmHg; P < 0.05). Capillary densities were similar in eNOS-/- mice and eNOS+/+ mice in the heart (4154 +/- 123 and 4051 +/- 247/mm2, respectively) and in skeletal muscle (961 +/- 40 and 1025 +/- 41/mm2, respectively). Arteriolar densities were 15% lower in skeletal muscle and in the heart in eNOS-/- mice than in the eNOS+/+ control group (P < 0.05). Hydralazine prevented hypertension and arteriolar rarefaction in eNOS-/- mice, whereas capillary density was unaffected by treatment with the vasodilator.
In young non-hypertensive eNOS-/- mice, the lack of eNOS did not affect microvascular densities in either of the muscles studied. In adult hypertensive eNOS-/- mice, we observed a lower arteriolar density, but a similar capillary density compared with controls. Hydralazine prevented hypertension and arteriolar rarefaction in adult mice, suggesting a non-NO-dependent pathway. Capillary density was not affected by hydralazine.
内皮型一氧化氮合酶基因敲除(eNOS-/-)小鼠的高血压被认为部分归因于血管舒张功能改变。然而,一氧化氮(NO)在血管生成中也起着重要作用。
研究eNOS-/-小鼠的毛细血管和小动脉密度是否受损,因为这可能是血管阻力增加和高血压的原因。
使用小鼠单克隆平滑肌α-肌动蛋白抗体进行免疫组织化学检测小动脉,使用兔多克隆纤连蛋白抗体检测毛细血管,我们对8周龄和12周龄的eNOS-/-小鼠左心室和股薄肌中的小动脉和毛细血管密度进行了量化,并与C57BL6J同窝小鼠(n = 6 - 8)进行比较。在第二组实验中,我们用降压血管扩张剂肼屈嗪治疗8周龄血压正常的eNOS-/-小鼠1个月。
8周龄的eNOS-/-小鼠血压正常,与eNOS+/+小鼠相比,其心脏和骨骼肌中的小动脉和毛细血管密度相似。12周龄的eNOS/-小鼠患有高血压(平均动脉压为118±21 mmHg,而对照组为64±2 mmHg;P < 0.05)。eNOS-/-小鼠和eNOS+/+小鼠心脏中的毛细血管密度相似(分别为4154±123和4051±247/mm²),骨骼肌中的毛细血管密度也相似(分别为961±40和1025±41/mm²)。eNOS-/-小鼠骨骼肌和心脏中的小动脉密度比eNOS+/+对照组低15%(P < 0.05)。肼屈嗪可预防eNOS-/-小鼠的高血压和小动脉稀疏,而血管扩张剂治疗对毛细血管密度无影响。
在年轻的非高血压eNOS-/-小鼠中,eNOS的缺失并未影响所研究的任何一种肌肉中的微血管密度。在成年高血压eNOS-/-小鼠中,我们观察到小动脉密度较低,但与对照组相比毛细血管密度相似。肼屈嗪可预防成年小鼠的高血压和小动脉稀疏,提示存在一条不依赖NO的途径。肼屈嗪对毛细血管密度无影响。